- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13:09 | Elicera Therapeutics to participate in upcoming investor and partnering events | 2 | Cision News | ||
| 17.09. | Elicera Therapeutics AB: Elicera Therapeutics Receives Medical Products Agency Approval to Advance CARMA Study into Phase IIa in B-cell Lymphoma | 203 | GlobeNewswire (Europe) | Uppsala, September 17, 2026 - Elicera Therapeutics AB (publ) announced today that the Swedish Medical Products Agency (Läkemedelsverket) has approved a substantial modification to the clinical trial... ► Artikel lesen | |
| 09.09. | Elicera Therapeutics AB: Elicera Therapeutics Receives Safety Committee Recommendation to Use Highest ELC-301 Dose as CARMA Moves Toward Phase IIa in B-cell Lymphoma | 208 | GlobeNewswire (Europe) | Uppsala, September 9, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 01.09. | Elicera Therapeutics AB: Elicera Therapeutics receives its first notice of patent allowance for ELC-201 - a Japanese patent protecting the oncolytic virus candidate against solid tumors | 167 | GlobeNewswire (Europe) | Uppsala, September 1, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 28.08. | Elicera Therapeutics AB: Elicera Therapeutics receives Notice of Allowance for U.S. patent application protecting the ELC-401 CAR T-cell candidate | 587 | GlobeNewswire (Europe) | Gothenburg, August 28, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 28.08. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 June 2026 | 225 | GlobeNewswire (Europe) | Second quarter (January-March 2026)
Operating profit/loss amounted to SEK -6,305,471 (-2,892,341)
Loss for the period amounted to SEK -6,261,763 (-2,732,070)
Cash flow from operating activities... ► Artikel lesen | |
| 18.08. | Elicera Therapeutics AB: Elicera Therapeutics appoints Johan Liwing as new CEO | 530 | GlobeNewswire (Europe) | Gothenburg, August 18, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 11.08. | ELICERA THERAPEUTICS AB: Last patient treated in the Phase I part of the CARMA study - tumor responses in 10 of 11 patients evaluated to date | 1 | Cision News | ||
| 11.08. | Elicera Therapeutics AB: Elicera Therapeutics: Last patient treated in the Phase I part of the CARMA study - tumor responses in 10 of 11 patients evaluated to date | 278 | GlobeNewswire (Europe) | Gothenburg, August 11, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 24.07. | Elicera Therapeutics AB: Elicera Therapeutics consolidates its management in Uppsala - CEO transition begins and recruitment of new CEO has started | 204 | GlobeNewswire (Europe) | Gothenburg, July 24, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 18.06. | Elicera Therapeutics Receives Positive Feedback from Swedish MPA on Planned Clinical Study with ELC-401 in Grade IV Glioma | 1 | Cision News | ||
| 03.06. | ELICERA THERAPEUTICS AB: Elicera publishes annual report for 2025 | 1 | Cision News | ||
| 01.06. | Elicera Therapeutics AB: Elicera announces outcome of the rights issue | 363 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 25.05. | Elicera Therapeutics AB: Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved | 506 | GlobeNewswire (Europe) | Gothenburg, May 25, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 13.05. | Elicera Therapeutics AB: Elicera Therapeutics' CSO takes temporary leave to undergo medical treatment - Di Yu appointed Acting CSO | 262 | GlobeNewswire (Europe) | Gothenburg, May 13, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 12.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.05.2026 | 1.514 | Xetra Newsboard | Das Instrument MIH0 US6067934041 MITSUBISHI HEAV.IN. ADR/1 EQUITY wird cum Kapitalmassnahme gehandelt am 12.05.2026 und ex Kapitalmassnahme am 13.05.2026 The instrument MIH0 US6067934041 MITSUBISHI... ► Artikel lesen | |
| 11.05. | Elicera Therapeutics AB: Elicera publishes information document regarding the rights issue | 408 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 21.04. | Elicera Therapeutics AB: Elicera Therapeutics carries out a rights issue of approximately SEK 73 million | 329 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 21.04. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2026 | 243 | GlobeNewswire (Europe) | First quarter (January-March 2026)
Operating profit/loss amounted to SEK -5,116,779 (-8,069,404).
Loss for the period amounted to SEK -5,060,060 (-8,013,462).
Cash flow from operating activities... ► Artikel lesen | |
| 20.03. | Elicera Therapeutics AB: Elicera Therapeutics Announces Swedish Cancer Society's Senior Investigator Award to Chief Development Officer Di Yu | 401 | GlobeNewswire (Europe) | Gothenburg, March 20, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 2,920 | -3,57 % | BERENBERG stuft Evotec auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Evotec nach einem Gespräch mit dem Konzernchef Christian Wojczewski mit einem Kursziel von 3,60 Euro auf "Hold" belassen.... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 648,50 | -0,78 % | Sanofi und Regeneron erweitern Allianz in Milliardendeal | DJ Sanofi und Regeneron erweitern Allianz in Milliardendeal
Von Adria Calatayud
DOW JONES--Sanofi und Regeneron Pharmaceuticals weiten ihre Kooperation zur gemeinsamen Entwicklung und Vermarktung... ► Artikel lesen | |
| BRAIN BIOTECH | 2,830 | +0,35 % | Brain Biotech erhält 11,5 Millionen Euro - hoher Buchungseffekt belastet | Brain Biotech erhält von Royalty Pharma eine Meilensteinzahlung von 11,51 Millionen Euro. Auslöser ist ein Entwicklungsfortschritt beim Pharmawirkstoff Deucrictibant auf Basis der 2024 geschlossenen... ► Artikel lesen | |
| SCORPIUS | - | - | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| CARDIOL THERAPEUTICS | 1,258 | -9,10 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
02.10.2026 / 12:56 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| CSL | 107,06 | -2,35 % | CSL Seqirus Expands U.S. Influenza Vaccine Availability Ahead Of Flu Season | CANBERA (dpa-AFX) - Tuesday, CSL Seqirus, a business of CSL (CSL.AX), said it has expanded the availability of influenza vaccines in the U.S. following the successful completion of its 2026/27... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,785 | 0,00 % | Burcon NutraScience Corp (2): Burcon NutraScience holders approve AGM resolutions | ||
| MANNKIND | 3,533 | +0,40 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,200 | -4,62 % | RBC Capital bestätigt Rating für Ocular Therapeutix und sieht Potenzial in AMD-Therapie | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,626 | +4,54 % | IP Group sells down stake in Oxford Nanopore | ||
| ADAPTIMMUNE THERAPEUTICS | 0,025 | -100,00 % | Merck And ADAP Crisis Task Force Reach Agreement To Expand IDVYNSO Access | ||
| CODEXIS | 1,232 | +1,48 % | Codexis, Inc.: Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA | REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| CORMEDIX | 6,542 | -0,97 % | CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | - Q2 2026 Consolidated Revenue of $101.9 million - - Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million - - Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance... ► Artikel lesen | |
| TELO GENOMICS | 0,035 | +15,00 % | Telo Genomics Corp.: Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing | In matched Cleveland Clinic and Jewish General Hospital samples, blood-based TELO enumeration detected circulating plasma cells in all Adaptive clonoSEQ-positive cases reviewed and in a series of clonoSEQ-negative... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 4,890 | -1,61 % | Aligos-Aktie +37%: Ein Vorbote für mehr? | Die Aligos-Aktie ist zum Wochenauftakt förmlich explodiert und schloss unter beachtlichen Umsätzen rund +37% höher. Für Anleger unserer Community ist das ein Déjà-vu: Bereits in der Vergangenheit haben... ► Artikel lesen |
ELICERA THERAPEUTICS AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,234 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.